Moderna, Inc. — Director's Dealing 2025

Mar 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-02-28

Reporting Person: Hoge Stephen (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-28	Common Stock	M	652	—	Acquired	1450728	Direct
2025-02-28	Common Stock	F	316	$31.09	Disposed	1450412	Direct
2025-02-28	Common Stock	M	611	—	Acquired	1451023	Direct
2025-02-28	Common Stock	F	296	$31.09	Disposed	1450727	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-28	Restricted Stock Units	$	M	652	Disposed		Common Stock (652)	Direct
2025-02-28	Restricted Stock Units	$	M	611	Disposed		Common Stock (611)	Direct
2025-03-01	Stock Option (Right to Buy)	$30.96	A	238043	Acquired	2035-03-01	Common Stock (238043)	Direct
2025-03-01	Restricted Stock Units	$	A	148524	Acquired		Common Stock (148524)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4116	Indirect
Common Stock	151933	Indirect

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.

F3: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F4: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F5: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F6: 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F7: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.